Ultragenyx Receives European Commission Decision for Evkeeza® (evinacumab) Expanded Indication in Children Aged 5 Years and Older with Homozygous Familial Hypercholesterolemia (HoFH)
18 déc. 2023 08h00 HE
|
Ultragenyx Pharmaceutical Inc.
NOVATO, Calif., Dec. 18, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that the European Commission (EC) has extended the approval of Evkeeza® (evinacumab) as...
Ultragenyx anuncia la aprobación de Crysvita® (burosumab) en México para el tratamiento de adultos que viven con hipofosfatemia ligada al cromosoma X (XLH)
11 déc. 2023 08h00 HE
|
Ultragenyx Pharmaceutical Inc.
CIUDAD DE MÉXICO, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), una compañía biofarmacéutica especializada en el desarrollo de productos novedosos para...
Ultragenyx to Participate at Investor Conferences in November
20 nov. 2023 16h30 HE
|
Ultragenyx Pharmaceutical Inc.
6th Annual Evercore ISI HealthCONx on November 28 in Miami Piper Sandler 35th Annual Healthcare Conference on November 29 in New York City NOVATO, Calif., Nov. 20, 2023 (GLOBE NEWSWIRE) --...
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
17 nov. 2023 16h30 HE
|
Ultragenyx Pharmaceutical Inc.
NOVATO, Calif., Nov. 17, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for...
Ultragenyx to Participate in the Jefferies London Healthcare Conference
07 nov. 2023 17h00 HE
|
Ultragenyx Pharmaceutical Inc.
NOVATO, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for...
Ultragenyx lancia in Italia Evkeeza® (evinacumab concentrato in soluzione per infusione) per il trattamento dell’ipercolesterolemia familiare omozigote (HoFH)
06 nov. 2023 02h00 HE
|
Ultragenyx Pharmaceutical Inc.
ROMA, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), azienda biofarmaceutica focalizzata sullo sviluppo e la commercializzazione di nuove terapie per malattie...
Ultragenyx Reports Third Quarter 2023 Financial Results and Corporate Update
02 nov. 2023 16h05 HE
|
Ultragenyx Pharmaceutical Inc.
Third quarter 2023 total revenue of $98.1 million, Crysvita® revenue of $74.9 million and Dojolvi® revenue of $16.6 million Reaffirmed 2023 expected total revenue guidance between $425 million to...
Ultragenyx anuncia que Mepsevii® (Vestronidasa alfa) ya está aprobado para su inclusión en el Compendio Nacional de Medicamentos de México para el tratamiento de la Mucopolisacaridosis VII (MPS VII)
01 nov. 2023 18h34 HE
|
Ultragenyx Pharmaceutical Inc.
CIUDAD DE MÉXICO, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc., una compañía biofarmacéutica dedicada al desarrollo y comercialización de terapias novedosas para...
Ultragenyx to Host Conference Call for Third Quarter 2023 Financial Results and Corporate Update
26 oct. 2023 16h05 HE
|
Ultragenyx Pharmaceutical Inc.
NOVATO, Calif., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for...
Ultragenyx Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters’ Option to Purchase Additional Shares
23 oct. 2023 16h01 HE
|
Ultragenyx Pharmaceutical Inc.
NOVATO, Calif., Oct. 23, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for...